Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ITCC-104: HEM-iSMART International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-Protocol E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT07175415 is registered in ClinicalTrials.gov with Princess Maxima Center for Pediatric Oncology as lead sponsor.

NCT NCT07175415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07175415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ITCC-104: HEM-iSMART International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-Protocol E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Lead sponsor
Princess Maxima Center for Pediatric Oncology
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2032
Enrollment
42 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, lymphoblastic lymphoma (precursor b-lymphoblastic lymphoma/leukaemia) recurrent, lymphoblastic lymphoma (precursor b-lymphoblastic lymphoma/leukaemia) refractory, lymphoblastic lymphoma (precursor t-lymphoblastic lymphoma/leukaemia) recurrent, lymphoblastic lymphoma (precursor t-lymphoblastic lymphoma/leukaemia) refractory